Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹8Cr
Rev Gr TTM
Revenue Growth TTM
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

GARODCH
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Profit Operating ProfitCr |
| | | | | | | | | | | | |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 33.3 | -400.0 | 0.0 | -300.0 | -50.0 | 80.0 | -1,000.0 | -25.0 | -300.0 | -500.0 | 3,754.6 | 40.0 |
| | | | | | | | | | | | |
| 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 | -0.2 | -0.1 | -0.2 | -0.1 | 5.6 | 0.0 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Profit Operating ProfitCr |
| | | | | | | | | | | | |
Other Income Other IncomeCr | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -2 | 6 | 0 | 3 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 4 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| -939.6 | 414.3 | -103.8 | 1,593.1 | -106.0 | -239.1 | 74.1 | 41.5 | 41.6 | -118.6 | -58.4 | 1,934.7 |
| | | | | | | | | | | | |
| -2.6 | 8.1 | -0.3 | 4.6 | -0.3 | -0.9 | -0.2 | -0.1 | -0.1 | -0.2 | -0.3 | 5.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| -19 | -13 | -14 | -10 | -11 | -11 | -11 | -12 | -12 | -12 | -12 | -8 |
Current Liabilities Current LiabilitiesCr | 11 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Non Current Liabilities Non Current LiabilitiesCr | 3 | 0 | 7 | 4 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 1 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Non Current Assets Non Current AssetsCr | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -1 | 0 | 0 | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing Cash Flow Financing Cash FlowCr | 1 | 0 | 0 | -4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
Free Cash Flow Free Cash FlowCr | -1 | 0 | 0 | 4 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
| 36.9 | -2.0 | 49.4 | -19.8 | -180.7 | 87.3 | 91.5 | 123.4 | 55.9 | 124.5 | 137.4 |
CFO To EBITDA CFO To EBITDA% | 1,046.0 | 53.9 | 99.7 | 453.1 | -180.7 | 87.3 | 91.5 | 123.4 | 55.9 | 124.4 | 137.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 7 | 10 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Price To Sales Price To Sales | | | | | | | | | | | |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.9 | -1.6 | -1.5 | -2.0 |
| -128.1 | -33.6 | -66.3 | -26.2 | -17.1 | -5.9 | -23.8 | -79.2 | -186.4 | -87.0 | -69.2 |
Profitability Ratios Profitability Ratios |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| 50.1 | 593.3 | -25.9 | 506.3 | -229.0 | -1,122.0 | 1,173.6 | -1,091.6 | 346.8 | -853.2 | -170.8 |
| 15.3 | -93.2 | 3.4 | -105.7 | 6.0 | 16.9 | 4.2 | 2.4 | 1.4 | 2.9 | 4.4 |
| -94.9 | 399.5 | -16.7 | 495.8 | -185.5 | -405.9 | -164.8 | -96.2 | -93.9 | -203.4 | -148.9 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
**Garodia Chemicals Limited** is an Indian **MSME** (Udyam Registration No. **UDYAM-MH19-0002293**) historically specialized in the manufacturing and trading of **dyes, chemicals, and chemical byproducts**. After a prolonged period of operational suspension and financial distress, the company is currently undergoing a comprehensive structural and financial revival following a court-approved **Resolution Plan** under the **Insolvency and Bankruptcy Code (IBC)**.
---
### 1. Current Corporate Status & Insolvency Resolution
The company’s recent history is defined by its transition from a **Corporate Debtor** to a revitalized entity. Following intense competition from the **China Market** and sustained losses, the company ceased operations, leading to a **Pre-packaged Insolvency Resolution Process (PPIRP)**.
* **NCLT Approval:** The **Hon’ble NCLT, Mumbai Bench**, approved the **Base Resolution Plan (BRP)** on **February 24, 2025**.
* **Resolution Applicant:** The plan was submitted jointly by the company and **Mr. Ravindra Subhash Salunkhe** (the Successful Resolution Applicant).
* **Monitoring Committee:** A committee was constituted on **May 28, 2025**, to oversee the implementation of the BRP and ensure compliance with the transition milestones.
* **Going Concern Status:** While financial statements for **FY 2024-25** were prepared on a **Non-Going Concern** basis (with assets/liabilities carried at **Fair Value**), the implementation of the BRP aims to restore commercial viability.
---
### 2. Capital Reconstitution & Shareholding Reset
To address the total erosion of net worth and settle creditor claims, the company is executing a significant restructuring of its equity base.
| Action Item | Impact on Shareholding | Key Date |
| :--- | :--- | :--- |
| **Promoter Extinguishment** | Full cancellation of **3,728,800** shares (**51.79%** stake) held by former promoters without payment. | **Dec 10, 2025** |
| **Public Consolidation** | Existing public shareholders receive **1** new share for every **13** shares held. | **Dec 10, 2025** |
| **Stock Sub-division** | Reduction of Face Value (FV) from **Rs. 10** to **Re. 1** per share. | **Mar 25, 2026** |
| **Authorized Capital** | Maintained at **INR 11,00,00,000** (1.10 Cr shares). | Current |
| **Paid-up Capital** | **INR 7,20,02,000** (Pre-restructuring). | Current |
---
### 3. New Governance Framework & Management
Under the approved BRP, the previous management (Mahesh Gordhandas Garodia, Kunal Nalin Naik, and Brian Lawrence Fernandes) has resigned, making way for a new leadership team appointed by the Resolution Applicant.
* **Managing Director:** **Mr. Ravindra Subhash Salunkhe** (Appointed for a 5-year term effective **March 10, 2025**, to **March 09, 2030**).
* **Board Reconstitution:**
* **Mrs. Bhagyashri Nilesh Devrale** (Non-Executive Non-Independent Director).
* **Mr. Vikram Ravindra Sabnis** (Independent Director).
* **Internal Controls:** The company is establishing a new framework including a **Risk Management policy** and an **Internal Audit System** to review **Standard Operating Procedures (SOPs)**.
---
### 4. Financial Performance & Debt Resolution
The company has reported **zero operating revenue** since **April 2019**. Recent financial statements reflect the costs of the insolvency process and the settlement of legacy liabilities.
**Standalone Financial Summary:**
| Metric (INR) | FY 2024-25 | FY 2023-24 | FY 2022-23 |
| :--- | :--- | :--- | :--- |
| **Total Revenue** | **0** | **75** | **0** |
| **Profit After Tax (Loss)** | **(20,76,622)** | **(13,10,909)** | **(5,99,716)** |
| **Dividend** | **Nil** | **Nil** | **Nil** |
**Debt Profile (as of NCLT Filings):**
* **Total Financial Debt:** **Rs. 4,41,21,594**.
* **Related Party Debt:** **Rs. 4,10,40,598** (Owed to former Director Mr. Mahesh Garodia).
* **Unrelated Financial Debt:** **Rs. 9,00,528** (Owed to M/s WZ Enterprises Private Limited).
* **Settlement Status:** Recent "Other Income" entries reflect the settlement of loans from former promoters and **M/s Garodia Sons Private Limited** as per the NCLT-approved plan.
---
### 5. Operational Restart Strategy
The primary objective of the new management is to leverage the company’s **MSME status** and historical industry classification to resume manufacturing.
* **Asset Profile:** Currently, the company has **Nil Fixed Assets** (no plant or machinery). The Resolution Applicant is responsible for infusing capital to acquire necessary infrastructure.
* **Core Focus:** Resumption of **chemical and chemical product manufacturing**.
* **Financial Projections:** The BRP includes specific projections (detailed in **Exhibit D** of the plan) intended to restore the company to profitability through new business activities.
---
### 6. Critical Risk Factors & Audit Qualifications
Investors should note significant historical lapses and ongoing risks identified by statutory auditors:
* **Material Uncertainty:** Auditors have previously expressed doubt regarding the company's ability to meet liabilities falling due within one year.
* **Internal Control Deficiencies:**
* Lack of an **Internal Audit System** commensurate with company size.
* Inability of auditors to conclude on the effectiveness of **Internal Financial Controls Over Financial Reporting (ICFR)**.
* Absence of third-party confirmations for **sundry creditors, debtors, and loans**.
* **Regulatory Non-Compliance:** Historical failures to appoint a **Women Director**, **CFO**, or **Internal Auditor**, and failure to maintain a **Structured Digital Database** under SEBI (PIT) Regulations.
* **Takeover Exemptions:** While the NCLT initially raised concerns regarding **SEBI Takeover Regulations**, the **NCLAT** clarified that the resolution plan is exempt from certain mandatory tender offer obligations under the IBC framework.
* **Subsidiaries:** The company has **no subsidiaries, associates, or joint ventures**, simplifying the corporate structure for the turnaround.